tbuckley/cabot-search huggingface dataset:
Genotyping melanoma in Colombia.
Authors: Hernan Carranza, Andres F. Cardona, Carlos A. Vargas, Pilar Archila, Jorge M. Otero, Laura Bernal, July Rodriguez, Jesus Insuasty, Henry A. Becerra, Andres Acevedo, Diego Lopera, Juan Alejo Jimenez, Mauricio Lema, Carlos Rojas, Isabel Cristina Durango, Andres Yepes, Leonardo Rojas, Ricardo Duarte, Gustavo Rojas, Oscar Arrieta
Journal: Journal of Clinical Oncology (2014)

e20054 Background: Melanoma has high clonal heterogeneity which follows a geographical pattern. The advent of therapy involving BRAF-specific inhibitors has enabled many efforts at exploring these neoplasias’ genotype around the world, documenting V600E and V600K alterations in about 50% of affected patients born in the USA, Western Europe and Australia. Few studies have evaluated the presence of alterations in the BRAF and KIT in the Hispanic population, finding a frequency between 39 and 77%, and 0%, respectively. Methods: 216 patients were explored for BRAF (V600E/V600K), NRAS (exons 1 and 2) and cKIT (exons 9, 11, 13 and 17) mutations using sequencing and RT-PCR (COBAS) techniques, following confirmation of histology and micro-dissection. Several outcomes were recorded in 98 cases. Results: median age was 55.4 years old on average (SD±13.8), 62% were older than 50 when diagnosed and 112 cases (52%) were female. When ascertaining the origin of the tumors 30% of the melanomas were found in skin which had been chronically exposed to sunlight, 43.1% could not be typed, 13.9% were acral-lentiginous melanomas, 7.9% were primary mucosal melanomas and 0.5% were uveal tumours. Tumour representation in paraffin-embedded tissue was good (80%), the site from which the sample was taken was usually the skin (43%), lymph nodes (24%), soft tissues (7%) and the lungs (6.5%). Tumour stage was greater than III in 75% and unknown in the rest. BRAF mutation frequency was 32.5% (67/206), 8.4% (11/131) for cKIT and 6.9% (9/131) for NRAS. KI67 was greater than 20% in 57% (101/175); this finding was greater in patients suffering lesions in chronically-exposed skin (p=0.054) and in those carrying a BRAF mutation (p=0.038). Median follow-up was 14.5-mo (95%CI 4.0-42.0) and overall survival was 18-mo (95%CI 16.8-19.1). Survival was modified by Clark (p=0.036) but not by different genotypes. Conclusions: The mutational profile of Colombian melanoma patients reported in this study differ with that described previously in other Western countries, especially for BRAF; however, such findings did agree with greater prevalence of mucosal and acral-lentiginous lesions.
Abstract P4-03-12: Cancer-associated fibroblasts release exosomal microRNAs that dictate an aggressive phenotype in breast cancer
Authors: G Condorelli, D Elvira, F Danilo, R Giuseppina, N Martina, A Assunta, A Alessandra, Q Cristina, P Salvatore, A Rienzo, T Renato
Journal: Cancer Research (2017)

Abstract This abstract was not presented at the symposium.
Relationship of RS4646 polymorphism in CYP19A1 gene to the efficacy of hormone therapy in early breast cancer.
Authors: Xiying Shao, Yabing Zheng, Lei Shi, Yuan Huang, Yuheng Ding, Yong Guo, Xiaojia Wang
Journal: Journal of Clinical Oncology (2015)

e11516 Background: Polymorphisms in the aromatase CYP19A1 gene have been shown to alter aromatase activity as well as circulating steroid hormone levels in postmenopausal women. The aim was to verify the potential association between CYP19A1 genetic polymorphisms and clinical outcome of hormone therapy in hormone receptor (HR) - positive early breast cancer. Methods: Genotyping for CYP19A1 rs4646 (C/A) polymorphism was performed on 287 Chinese women with HR-positive early breast cancer in Zhejiang Cancer Hospital. Associations were evaluated between CYP19A1 rs4646 genotypes and disease-free survival (DFS). Results: Overall, women with the minor allele (AA or AC) had an improved DFS when compared with those carrying the homozygous common allele (CC) (62.7 months versus 55.6 months; HR, 0.745; 95% CI, 0.562-0.988; p = 0.04). The difference was further demonstrated by multivariate analyses (HR, 0.681; 95 % CI, 0.506-0.917; p = 0.011). In premenopausal women, AA genotype was associated with a prolonged DFS (98.2 months versus 56.2 months; HR, 0.425; 95 % CI, 0.198-0.914; p = 0.024). Women with A allele had an improved DFS when compared with those carrying the homozygous C allele ( 62.7 months versus 55.6 months; HR, 0.709; 95% CI, 0.516-0.975; p = 0.033). These foundings were further confirmed by multivariate analyses (HR, 0.336, 0.670; 95 % CI, 0.160-0.836, 0.479-0.938; p = 0.017, 0.019). In postmenopausal women, rs4646 genotypes were significantly associated with DFS ( 32.7 months versus not reached versus 56.3 months; p = 0.011). Women carrying AA variant had a poorer DFS than those with CC or AC genotypes (32.7 months versus 70.6 months; HR, 3.613; 95 % CI, 1.380-9.457; p = 0.005). Furthermore, these findings were confirmed by multivariate analyses (HR, 3.614; 95 % CI, 1.308-9.991; p = 0.013). Conclusions: The homozygous minor allele (AA) is significantly associated with improved clinical outcome of hormone therapy in premenopausal early breast cancer patients, but with a worse impact on postmenopausal women. The foundings are novel, if confirmed, genotyping for CYP19A1 rs4646 polymorphism may provide predictive information for better selection of endocrine treatment.
Abstract IA28: Innovative PDX models for studying immunotherapy of cancer
Authors: Miguel F. Sanmamed
Journal: Clinical Cancer Research (2016)

Abstract PDX models are limited by the absence of a complete and functional immune system. Overwhelming evidence now exists to suggest that immune cells play an integral role in the development and maintenance of tumors. Without a functional immune system, PDX models cannot reflect the dynamic processes of tumor-immune surveillance and immune-mediated editing, limiting the translation of antitumor results obtained in these models. Another important consequence of lacking an immune system is the impossibility to test in these models anticancer drugs that directly target immune cells. To overcome these important limitations, PDX models with human immune systems are needed. There are different approaches to enrich PDX models with human immune cells: engrafting human peripheral blood mononuclear cells, engrafting hematopoietic stem cells, or engrafting primary patient-derived tumor xenografts with human tumor infiltrating lymphocytes. All these alternatives have different strengths and weaknesses that are important to know for obtaining preclinical results that are meaningful for clinical translation. Citation Format: Miguel F. Sanmamed. Innovative PDX models for studying immunotherapy of cancer. [abstract]. In: Proceedings of the AACR Special Conference: Patient-Derived Cancer Models: Present and Future Applications from Basic Science to the Clinic; Feb 11-14, 2016; New Orleans, LA. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(16_Suppl):Abstract nr IA28.
Abstract P4-03-09: Human breast cancer biopsies induce eosinophil recruitment and enhance adjacent cancer cell proliferation
Authors: BL Spencer, G Szalayova, A Ogodnik, M Rincon, T James
Journal: Cancer Research (2017)

Abstract Previous research has demonstrated that chronic inflammation facilitates cancer progression and spread to other sites. The effect of acute inflammation in the microenvironment of the tumor that develops as a result of standard biopsy procedures has not been studied in detail. Recent studies demonstrated that acute inflammation in mouse models from a mammary biopsy increases the frequency of distal cancer metastasis. Core needle biopsies are the standard procedure for breast cancer diagnosis, but there have been no studies detailing the inflammatory response from the biopsy. The purpose of this study is to determine if core needle biopsies in breast cancer patients trigger an inflammatory response, determine the type of inflammatory response that occurs and study the potential effect of acute inflammatory response on tumor cells remaining. The biopsy wound site was identified in primary tumor resection samples from breast cancer patients. The inflammatory response adjacent and distant to the biopsy were studied via histology and immunohistochemistry. Tumor cell proliferation was studied as well. Our study demonstrated that diagnostic core needle biopsies trigger inflammatory cell recruitment at the site, and those cells remain over long periods of time. An unexpected increase in eosinophils were found to accumulate at the biopsy site. The biopsy also was shown to increase proliferation adjacent to the wound site. Overall, core needle biopsies used for breast cancer diagnosis induce a unique inflammatory environment at the site of the biopsy as well as the closely surrounding cells. Inflammation induced by the biopsy could lead to tumor cell progression or metastasis in breast cancer. These findings may be important for the clinical management of breast cancer. Citation Format: Spencer BL, Szalayova G, Ogodnik A, Rincon M, James T. Human breast cancer biopsies induce eosinophil recruitment and enhance adjacent cancer cell proliferation [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-03-09.
Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia
Authors: Juan Feng, Yan Li, Yujiao Jia, Qiuyun Fang, Xiaoyuan Gong, Xiaobao Dong, Kun Ru, Qinghua Li, Xingli Zhao, Kaiqi Liu, Min Wang, Zheng Tian, Yannan Jia, Ying Wang, Dong Lin, Hui Wei, Kejing Tang, Yingchang Mi, Jianxiang Wang
Journal: Journal of Hematology & Oncology (2017)

Target-specific next-generation sequencing technology was used to analyze 112 genes in adult patients with acute lymphoblastic leukemia (ALL). This sequencing mainly focused on the specific mutational hotspots. Among the 121 patients, 93 patients were B-ALL (76.9%), and 28 patients (23.1%) were T-ALL. Of the 121 patients, 110 (90.9%) harbored at least one mutation. The five most frequently mutated genes in T-ALL are NOTCH1, JAK3, FBXW7, FAT1, and NRAS. In B-ALL, FAT1, SF1, CRLF2, TET2, and PTPN1 have higher incidence of mutations. Gene mutations are different between Ph+ALL and Ph−ALL patients. B-ALL patients with PTPN11 mutation and T-ALL patients with NOTCH1 and/or FBXW7 mutations showed better survival. But B-ALL with JAK1/JAK2 mutations showed worse survival. The results suggest that gene mutations exist in adult ALL patients universally, they are related with prognosis.
The Results of a Phase I Study using Velcade (Bortezomib), Cladribine, and Rituximab (VCR) in treating Mantle Cell Lymphoma
Authors: Jeffrey J. Pu, W. Christopher Ehmann, Jason Liao, Christine Capper, Michelle Levy, David F. Claxton, Witold B. Rybka, Raymond J. Hohl, Elliot M. Epner
Journal: Blood (2016)
Scientists Receive Award for Meningitis Vaccine Research
Authors: Rebecca Voelker
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Phase I Trial of CpG-7909, Rituximab Immunotherapy, and Y90 Zevalin Radioimmunotherapy for Patients (Pts) with Previously Treated CD20+ Non-Hodgkin Lymphoma (NHL).
Authors: Thomas E. Witzig, Gregory A. Wiseman, George Weiner, Stephen M. Ansell, Ivana Micallef, Thomas M. Habermann, Clive S. Zent, David J. Inwards, Tait Shanafelt, Luis Porrata, Matthew J. Maurer, Cristine Allmer, Zuhair Ballas
Journal: Blood (2007)
Abstract IA07: Single cell functional proteomics and metabolomics: A conduit to physicochemical models of tumor biology
Authors: James R. Heath
Journal: Cancer Research (2017)

Abstract Advances in single cell methods have opened up fundamentally new ways to think about biology. One new concept involves specific experiments that provide a direct and quantitative bridge between complex biological phenomena and the physico-chemical laws. To this end, we have developed microchip-based methods for measuring large panels of functional proteins and metabolites from statistical numbers of single cells. Functional proteins include secreted signaling proteins that provide measures of immune cell behaviors, and phosphorylated (activated) enzymes that reflect intracellular signaling flux and are often hyperactivated (and thus constitute drug targets) in cancers. For metabolites, we have focused on those associated with cellular energy flux. Importantly, cells sense and respond to their environments by adjusting the levels of such analytes. The following observations are the basis for connecting such measurements to the physico-chemical laws: 1. Cells are finite systems in a thermodynamic sense. This means that otherwise identical cells will have different numbers of the measured analytes. 2. A histogram of levels of the analytes versus frequency of observation across many single cells represents the fluctuations of those cells. In the maximum entropy formulation of thermodynamics, fluctuations can be used to identify the stable steady state of the cells (the state of minimum free energy), as well as constraints that prevent (constrain) the cells from reaching that steady state. 3. When many analytes are measured from the same cells, analyte-analyte correlations are extracted. If the measurements are quantitative (as are ours), then relationships between the chemical potential of a given analyte and its copy numbers is established. These to values represent cognate intensive and extensive parameters, and can allow for precise predictions for how cells respond to a weak perturbation through the Principle of Le Chatelier. They also provide an approach for distinguishing between weak and strong perturbations, since strong perturbations cause a cell-state change, while weak perturbations do not. In this talk, I will discuss provide detail on the above described experimental platforms, and describe how analyses based on these concepts can yield insight into clinically meaningful problems associated with therapy resistance in glioblastoma and melanoma. Citation Format: James R. Heath. Single cell functional proteomics and metabolomics: A conduit to physicochemical models of tumor biology. [abstract]. In: Proceedings of the AACR Special Conference on Engineering and Physical Sciences in Oncology; 2016 Jun 25-28; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2017;77(2 Suppl):Abstract nr IA07.
Analysis of the IDH1G105 (SNPrs11554137) Polymorphism in 961 AML Patients and in a Large Cohort of 475 Healthy Controls
Authors: Susanne Schnittger, Christiane Eder, Tamara Alpermann, Thomas Illig, Norman Klopp, H.-Erich Wichmann, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach
Journal: Blood (2011)
General practice opening hours to be scrutinised
Authors: Adrian O’Dowd
Journal: BMJ (2017)

From October general practices in England will be financially penalised if they close during core working hours during the week, the chief executive of NHS England has said.

Simon Stevens told MPs on the House of Commons Public Accounts Committee that changes to the GP contract, which will be introduced in October, will allow NHS England to scrutinise GP opening hours more closely and take action where necessary.

MPs were reviewing progress on access to general practice after a report was published in January by the financial watchdog the National Audit Office.1 The report said that though the government’s intention to improve access to general practice in the evenings …
Sex and Gender Reporting in Research
Authors: Bruce E. Wexler
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Ratio of ADAMTS13 to VWF-Propeptide Can Reflect the Disease Severity and the Extent of Inflammation of the Patients with Severe Sepsis or Septic Shock,
Authors: Kenji Nishio, Hidetada Fukushima, Tomoro Watanabe, Tadahiko Seki, Hideto Matsui, Mitsuhiko Sugimoto, Masanori Matsumoto, Yoshihiro Fujimura, Kazuo Okuchi
Journal: Blood (2011)
Fc-Gamma Receptor Polymorphisms Are Associated with Susceptibility to and Recovery from Pediatric Immune Thrombocytopenia
Authors: Katja M.J. Heitink-Polle, Annemieke G. Laarhoven, Marrie C.A. Bruin, Barbera Veldhuisen, Sietse Q. Nagelkerke, Taco Kuijpers, C. Ellen van der Schoot, Gestur Vidarsson, Masja de Haas
Journal: Blood (2016)
Medullary Carcinoma
Authors: R Michael Tuttle, Douglas W Ball, David Byrd, Gilbert H Daniels, Raza A Dilawari, Gerard M Doherty, Quan-Yang Duh, Hormoz Ehya, William B Farrar, Robert I Haddad, Fouad Kandeel, Richard T Kloos, Peter Kopp, Dominick M Lamonica, Thom R Loree, William M Lydiatt, Judith McCaffrey, John A Olson, Lee Parks, John A Ridge, Jatin P Shah, Steven I Sherman, Cord Sturgeon, Steven G Waguespack, Thomas N Wang, Lori J Wirth
Journal: Journal of the National Comprehensive Cancer Network (2010)
Intravenous Forodesine (BCX-1777), a Novel Purine Nucleoside Phosphorylase (PNP) Inhibitor, Demonstrates Clinical Activity in Phase I/II Studies in Patients with B-Cell Acute Lymphoblastic Leukemia.
Authors: Richard R. Furman, Varsha V. Gandhi, J. Claude Bennett, Shanta Bantia, J. Michael Kilpatrick
Journal: Blood (2004)
HSC Clonal Dynamics after T-Cell Depletion in a Nonhuman Primate Model of Lentiviral Gene Therapy
Authors: Sanggu Kim, Robert E Donahue, Gajendra Suryavanshi, Balamurugan Arumugam, Aylin C Bonifacino, Yiming Xie, Otto Yang, Cynthia E. Dunbar, Irvin Chen
Journal: Blood (2016)
Annals Story Slam - Eeyore and Tigger
Authors: Benjamin Khazan
Journal: Annals of Internal Medicine (2017)

Web Exclusives7 March 2017Annals On Being a Doctor Story Slam - Eeyore and TiggerFREEBenjamin Khazan, MDBenjamin Khazan, MDFrom Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W17-0031 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - Eeyore and Tigger "Eeyore and Tigger," by Dr. Benjamin Khazan (Duration 6:55)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: From Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.Current Author Address: Benjamin Khazan, MD; e-mail, benjamin.[email protected]edu. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 7 March 2017Volume 166, Issue 5Page: SS1 ePublished: 7 March 2017 Issue Published: 7 March 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.Loading ...
Diagnostic Accuracy of Noninvasive Fibrosis Scores in a Population of Individuals With a Low Prevalence of Fibrosis
Authors: Suzanne E. Mahady, Petra Macaskill, Jonathan C. Craig, Grace L.H. Wong, Winnie C.W. Chu, Henry L.Y. Chan, Jacob George, Vincent W.S. Wong
Journal: Clinical Gastroenterology and Hepatology (2017)
Phase I trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A Children’s Oncology Group Study.
Authors: Robin Elizabeth Norris, Elizabeth Fox, Joel M. Reid, Andrew T. Ralya, Xiaowei Liu, Charlotte H. Ahern, Charles Minard, Jodell Dahl, Rachel Eubank, Brenda Weigel
Journal: Journal of Clinical Oncology (2015)

10036 Background: Ontuxizumab is a humanized IgG mAb that targets the cell-surface glycoprotein endosialin (TEM-1/CD248). Endosialin is found in tumor stroma and vasculature across various tumors, with high expression in sarcoma and neuroblastoma but generally limited expression in normal tissue. Ontuxizumab binding to endosialin may interfere with platelet-derived growth factor (PDGF) signaling and prevention of protein interactions involved in tumor-stroma organization and new vessel formation. Methods: Ontuxizumab was administered intravenously on days (d) 1, 8, 15, and 22 of a 28 d cycle. Three dose levels (4, 8, and 12mg/kg) were evaluated using a rolling 6 design. Further dose escalation to 16mg/kg would proceed only if the ontuxizumab systemic clearance (CL) was ≥ 30% higher in children compared to adults and the maximum tolerated dose (MTD) was not reached. Primary endpoints were to describe toxicities, define MTD or recommended phase 2 dose (RP2D) and to characterize the pharmacokinetics (PK) of ontuxizumab in children. Following determination of MTD/RP2D an additional cohort of 6 pts < 12y was enrolled. PK was evaluated using non-compartmental and population PK modeling. Results: Twenty-seven eligible pts (17 male, median age 15y, range 3 – 21y) were enrolled. Twenty-two pts [neuroblastoma (5), Ewing sarcoma (4), rhabdomyosarcoma (4), other (9) tumors] were fully evaluable for toxicity. Five pts did not complete cycle 1 due to tumor progression. Grade ≥ 3 regimen-related non-hematologic toxicities included hypophosphatemia (1) and hyponatremia (1). One pt had grade 3 lymphopenia and 1 pt had grade 3 anemia in cycle 1. Grade ≤ 2 fever or infusion related reactions occurred in 9 pts. Dose-limiting bacteremia was observed during cycle 1 in 1 pt at dose level 3 (12mg/kg). Clearance was dose-dependent and within 30% of adult value (0.193 mL/h/kg) at 12mg/kg. Therefore there was no further dose escalation. Conclusions: The recommended dose of ontuxizumab in children is 12mg/kg administered weekly. This dose appears to be well tolerated in children with relapsed or refractory solid tumors. PK does not appear to be significantly different in children compared to adults. Clinical trial information: NCT01748721.